• Home
  • >
  • English
  • >
  • Faculty


김세호 교수님
  • Major : Molecular Immunology/Antibody Engineering
  • Research field : Antibody Engineering/ Process, Preclinical &
    Clinical Development of Therapeutic Antibodies
  • Phone : 033-250-6089
  • e-mail : kimsho@kangwon.ac.kr
days academic ability
1983 B.S. Dept. of Agricultural Chemistry. Seoul National University, Seoul, Korea
1990 M.S. Dept. of Animal Science. Kon-Kuk University, Seoul, Korea
1998 Ph.D. Dept. of Immunology. The Weizmann InstituteofScience, Rehovot, Israel
Professional Experience
days career
1983 ~ 2013 Research Center, Green Cross Corp., Korea (Research Scientist, Senior Research Scientist, Research Director)
1997 ~ 1999 Postdoctoral research fellow. Antibody Engineering lab., Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
2013 ~ Present University-Industry Cooperation Foundation & Dept. of Systems Immunology, Kangwon National University, Chuncheon, Kangwon-Do, 200-701, Korea
Ph.D. Thesis
  • A genetic approach to elucidate the mechanism of antibody-mediated catalysis using esterolytic antibodies as a model system
  • Chung YS, Son JK, Choi B, Joo SY, Lee YS, Park JB, Moon H, Kim TJ, Kim SH, Hong S, Chang J, Kang MS, Kim SJ (2015) Co-transplantation of human fetal thymus, bone and CD34+ cells into young adult immunodeficient NOD/SCID IL2Rγnull mice optimizes humanized mice that mount adaptive antibody responses. Clin Immunol. 157: 156-165
  • Cho KJ, Hong KW, Kim SH, Seok JH, Kim S, Lee JH, Saelens X, Kim KH (2014) Insight into highly conserved h1 subtype-specific epitopes in influenza virus hemagglutinin. PLoS One. 9(2): 1-9
  • Shin TH, Sung ES, Kim YJ, Kim KS, Kim SH, Kim SK, Lee YD, Kim YS (2014) Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the anti-tumor efficacy. Mol Cancer Ther. 13(3):1-11
  • Park GC, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Shin YW, Kim SH, Chang KH, Namgoong JM, Park CS, Park HW, Park YH, Kang SH, Jung BH, Lee SG (2013) Analysis of S gene mutation of the hepatitis B virus in adult liver transplant recipients showing resistance to hepatitis B immunoglobulin therapy. Transplant Proc. 45(8):3047-511
  • Cho KJ, Lee JH, Hong KW, Kim SH, Park Y, Lee JY, Kang S, Kim S, Yang JH, Kim EK, Seok JH, Unzai S, Park SY, Saelens X, Kim CJ, Lee JY, Kang C, Oh HB, Chung MS, Kim KH (2013) Insight into structural diversity of influenza virus hemagglutinin. J Gen Virol.
  • Chang KH, Kim MS, Hong GW, seo MS, Shin YN, Kim SH (2012) Affinity Maturation of an Epidermal Growth Factor Receptor Targeting Human Monoclonal Antibody ER414 by CDR Mutation. Immune Network 12(4):155-64
  • Chang KH, Kim MS, Hong GW, Shin YN, Kim SH (2012) Conversion of an EGFR targeting murine monoclonal antibody A13 to a human monoclonal antibody by guided selection. Experimental & Molecular Medicine 44 (1):52-59.
  • Hong KW, Kim CG, Lee SH, Chang KH, Shin YW, Ryoo KH, Kim SH*, Kim YS. (2010) A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab. J Biotechnol. 145(1):84-91.
  • Kim SH*, Shin YW, Hong KW, Chang KH, Ryoo KH, Paik SH, Kim JM, Brotman B, Pfahler W, Prince AM (2008) Neutralization of hepatitis B virus (HBV) by human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees. Antiviral Res. 79(3):188-91
  • Kim SH*, Oh HK, Ryu CJ, Park SY, Hong HJ (2008) In vivo hepatitis B virus-neutralizing activity of an anti-HBsAg humanized antibody in chimpanzees. Experimental and Molecular Medicine 40(1): 145-149.
  • Shin YW, Ryoo KH, Hong KW, Chang KH, Choi JS, So M, Kim PK, Park JY, Bong KT, Kim SH*. (2007) Human monoclonal antibody against hepatitis B virus surface antigen (HBsAg). Antiviral Res. 75(2):113-20.
  • Hong HJ, Ryu CJ, Hur H, Kim SH, Oh HK, Oh MS, Park SY. (2004) In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 318(1):134-141.
  • Kim SH*. (2003) Expression and purification of recombinant immunotoxin - a fusion protein stabilizes a single-chain Fv (scFv) in denaturing condition. Protein Expr Purif. 27(1):85-89.
  • Kim SH* and Park SY (2002) Selection and characterization of human antibodies against hepatitis B virus surface antigen (HBsAg) by phage-display. Hybridoma and Hybridomics 21 (5):385-392.
  • Lindner AB, Kim SH, Schindler DG, Eshhar Z, Tawfik DS. (2002) Esterolytic antibodies as mechanistic and structural models of hydrolases-a quantitative analysis. J Mol Biol. 320(3):559-572.
  • Kim SH*, Chun JH, Park SY. (2001) Characterization of monoclonal antibodies against carcinoembryonic antigen (CEA) and expression in E. coli. Hybridoma 20 (4): 265-272.
  • Kim SH*, Song SH, Kim YJ, Park SY. (2001) Expression and characterization of a recombinant Fab fragment derived from an anti-human alpha-fetoprotein (AFP) monoclonal antibody. Mol & Cells 11 (2): 158-163.
  • Kim SH*. (2001) Development of a one-step two-site enzyme immunoassay for measuring human alpha-fetoprotein by eliminating hook-effect. J. Biochem. & Mol. Biol. 34 (1): 47-50.
  • Yun JW, Lee SY, Choi BW, Oh HK, Kim SH, Byun TH, Park SY. (2000) Continuous stable production of von Willebrand Factor monoclonal antibody in spin filter bioreactor with bleeding technology. Biotechnol. Bioprocess Eng 5 (2): 130-135
  • Kim SH, Titlow CC, Margolies MN. (2000) An approach for preventing recombination-deletion of the 40-50 anti-digoxin antibody V(H) gene from the phage display vector pComb3. Gene 241 (1):19-25.
  • Kim SH, Schindler DG, Lindner AB, Tawfik DS, Eshhar Z. (1997) Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies. Mol Immunol 34 (12-13):891-906.
  • Charbonnier JB, Golinelli-Pimpaneau B, Gigant B, Tawfik DS, Chap R, Schindler DG, Kim SH, Green BS, Eshhar Z, Knossow M. (1997) Structural convergence in the active sites of a family of catalytic antibodies. Science 275 (5303):1140-1142.
  • Tawfik DS, Lindner AB, Chap R, Kim SH, Green BS, Eshhar Z. (1997) CatELISA: ELISA-based detection of catalytic antibodies and enzymes. Immunology Methods Manual (edited by Ivan Lefkovits). Section 8.8, p553-560. Academic Press, London.
  • Kim SH, Kim CK, Kwon OJ, Chung KS, Kim JB. (1990) Development of immunochemiluminometric assay (ICMA) for the measurement -fetoprotein (AFP) and mapping of the antigenic epitopes of AFP. Bioluminescence and Chemiluminescence-Current Status (edited by Philip E. Stanley & Larry J. Kricka). P199-202. John Wiley & Sons.
  • Kim SR, Suh PG, Juhnn YS, Kim SH, Chung HK, Kimm SW. (1988) Purification of -fetoprotein from cord serum by monoclonal immunoaffinity chromatography. Korean J. of Biochem. 20 (2), 93-98.
  • 김세호 (2011) 바이오시밀러 정의 및 타깃. 과학과 기술 (The Science & Technology). Vol.506, 14-18.
  • 김세호 (2002) 치료항체공학 (Therapeutic antibody engineering). Bioindustry 31 (한국생물산업협회). P36-41.
  • Kim SH*, Oh HK, Jung SM, Byun TH, Hong HJ, Park SY (1999) Development of therapeutic humanized antibodies against surface antigens of hepatitis B virus. A symposium on the recent trend of development of therapeutics against liver diseases, p8-10, 덕성여대 약학 심포지움.
1 Human antibodies against the surface antigen of HBV KR0467706 2005.1.13
2 Anti-carcinoembryonic antigen monoclonal antibody and single chain fv prepared therefrom KR0473713 2005. 2.18
3 Plasmid to be inserted with variable region of human antibodies against the surface antigen of HBV KR0523732 2005.10.18
4 vector DNA expressing scFv for producing scFv antibody library KR0635370 2006.10.11
5 monoclonal antibodies having neutralizing activity against tetanus toxoid and hybridoma cell lines producing the same KR0624011 2006.9.7
6 monoclonal antibody against epidermal growth factor receptor and hybridoma cell line producing the same), KR0680141 2007.2.1
7 monoclonal antibody against B-lymphoma and hybridoma cell line producing the same), KR0701923 2007.3.26
8 (Antibodies specifically binding to the epidermal growth factor receptor) KR1108642 2012.1.16
PCT/KR2009/006380 2009.11.2
PCT/KR2010/004445 2010. 7.8
10 Epitope and its use of Hepatitis B virus surface antigen KR10-2011-0064671 2011. 6. 30
PCT/KR2011/005477 2011.7.25
11 Three dimensional structure of EGF receptor and its epitope U.S. Provisional Application 61/616,073 2012.3.27
12 Epitope on the EFG receptor and its use PCT/KR2013/002550 2013.3.27
13 An antibody composition for prevention or treatment of mutant hepatitis B virus infection} KR10-2012-0075063 2012.7.10
PCT/KR2013/006025 2013.7.8
(우 : 24341) 강원도 춘천시 효자2동 강원대학길1 강원대학교 의생명과학관 A205호
TEL : 033)250-8380 | FAX : 033)259-5643